Working for better medicine

We are committed to improving healthcare by researching and developing innovative solutions for disease prevention, management and cure.

Italfarmaco Nordics

– an overview

More than 85 years ago, ITALFARMACO Group (ITF) was founded, driven by the passion to develop medicines in a wide range of disease areas. The company is one of the leading global Italian companies and operates in both the pharmaceutical and fine chemical industries.

Italfarmaco Nordics was established in 2024 and specializes in the area of ​​Rare diagnoses. Our office is located in Stockholm, and we work in all Nordic countries. In collaboration with global expertise within ITALFARMACO Group, we look forward to contributing with valuable development and new treatment options.

Unusual is usual for us

Our goal is to improve the health and quality of life of those living with rare diagnoses. In our research and development, we start from the needs of patients to create innovative therapies and contribute with long-term results. Initially, we focus on neuromuscular diseases and especially Duchenne muscular dystrophy (DMD).

0 K

Lorem ipsum dolor sit amet, consectetur adipiscing elit

0 K

Lorem ipsum dolor sit amet, consectetur adipiscing elit

0 K

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Our History

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt.

Meet our Leaders

Francesco De Santis, Chairman Italfarmaco SpA

Francesco
De Santis

Chairman
Italfarmaco

Bio
Carlos Barallobre, CEO Italfarmaco SpA

Carlos
Barallobre

CEO
Italfarmaco

Bio

Kristina
Grafström

Head of Rare Diseases Cluster Nordics
Italfarmaco Nordics

Bio

Evolution: how to make treatments more accessible for more patients

Pharmaceutics is a dynamic science, constantly evolving to make every medicine, formula, and application more effective. Our commitment to accessibility drives us to provide significant benefits and enable more people to access targeted and effective treatments. In our four research hubs, we focus on identifying new dosing solutions for approved drugs, repurposing reformulations, and developing APIs to deliver high-quality generic medicines to the market, ensuring that healthcare is more inclusive.

News & Highlights

Lorem ipsum dolor sit amet, consectetur adipiscing elit

  • 2024 - September 6

    World Duchenne Awareness Day 2024

    7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.

  • 2024 - June 28

    Italfarmaco partners with Iktos on Artificial Intelligence to speed drugdiscovery breakthroughs for patients

    Combines AI to increase the potential of novel histone deacetylase (HDAC) inhibitors in the non-oncological field

  • 2023 - September 7

    Duchenne Awareness DAY 2023

    7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.

  • 2022 - September 7

    Duchenne Awareness DAY 2022

    September 7th is World Duchenne Muscular Dystrophy Awareness Day, a disease that sees us, as a company, at the forefront of the search for a drug that can slow down its progression.